How many other drugs would they have which could simultaneously:
a) extend their patent life by up to 20 years,
b) expand their patient population to include people with a history of cardiac problems,
c) increase the effectiveness of Kyprolis, and,
d) result in less severe side-effects in patients receiving Kyprolis.
I would expect the list is not that long.
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-56
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
